US EditionOmeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
Summary by Enid News & Eagle
3 Articles
3 Articles
All
Left
1
Center
1
Right
#Omeros Corporation Drives Forward with Promising Phase 3 Trials and Regulatory Strategies for Innovative C...
In an encouraging move for advancing innovative treatments in rare diseases, Omeros Corporation (Nasdaq: OMER) recently announced several significant updates regarding its novel complement inhibitors: zaltenibart and narsoplimab. Based in Seattle, Omeros has been at the forefront of developing transformative therapies that target the complement system, a complex part of the immune system, to address conditions with unmet medical needs. 'Zaltenib…
Coverage Details
Total News Sources3
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
